• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.16% Nasdaq Up0.25%

    Halozyme Therapeutics, Inc. (HALO)

    -NasdaqGS
    17.88 Up 0.53(3.05%) 4:00PM EDT
    |After Hours : 17.85 Down 0.03 (0.17%) 7:18PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Halozyme Therapeutics, Inc.
    11388 Sorrento Valley Road
    San Diego, CA 92121
    United States - Map
    Phone: 858-794-8889
    Fax: 858-704-8311
    Website: http://www.halozyme.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:153

    Business Summary 

    Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter abnormal tissue structures for clinical benefit. The company’s products are based on the Enhanze technology, a patented human recombinant hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs; in subcutaneous urography; and to enhance resorption of radiopaque agents. The company is also developing PEGPH20, a new molecular entity that is in Phase II clinical trials for the treatment of metastatic pancreatic cancer, as well as in Phase I clinical trial for the treatment of non-small cell lung cancer; and Hylenex recombinant for use as pre-treatment in patients with type 1 diabetes using pumps and recombinant human cathepsin L (HTI-501) for the treatment of cellulite. It has collaborative partnerships with F. Hoffmann-La Roche, Ltd., Hoffmann-La Roche, Inc., Baxter Healthcare Corporation, Pfizer Inc., and Janssen Biotech, Inc. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Halozyme Therapeutics, Inc.

    Corporate Governance 
    Halozyme Therapeutics, Inc.’s ISS Governance QuickScore as of May 1, 2015 is 10. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 10; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Dr. Helen I. Torley M.B. Ch. B., M.R.C.P., 52
    Chief Exec. Officer, Pres and Director
    2.20M0.00
    Mr. David A. Ramsay MBA, 50
    Chief Financial Officer and VP
    503.00K481.00K
    Mr. William J. Fallon , 58
    VP of Manufacturing and Operations
    N/AN/A
    Mr. James S. Mazzola ,
    VP of Corp. Communications & Investor Relations
    N/AN/A
    Mr. Harry J. Leonhardt Esq., 58
    Chief Compliance Officer, Sr. VP , Gen. Counsel and Corp. Sec.
    N/AN/A
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders